Pharming Group N.V. (PHAR) Price Target Analysis
Updated Jun 26, 2026
Analyst Rating: Buy
Based on 2 analysts184.9% Below Target
PHAR trades 184.9% below Wall Street's consensus target of $38.00.
Current Price$13.34
Average Target$38.00
Target
Current
Low$37.00
Median$37.00
High$40.00
Analyst Target Range
Forward P/E68.3x
(High Premium)
PEG Ratio—
Implied Growth-99.7%
(Declining)
Analyst Spread7.9%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PHAR achieves its forward estimates and maintains a stable P/E multiple of 68.3x. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PHAR Price Target Analysis
Updated June 28, 2026As of June 28, 2026, Pharming Group N.V. (PHAR) has a Wall Street consensus price target of $38.00, based on estimates from 2 covering analysts. With the stock currently trading at $13.34, this represents a potential upside of +184.9%. The company has a market capitalization of $936M.
Analyst price targets range from a low of $37.00 to a high of $40.00, representing a 8% spread in expectations. The median target of $37.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PHAR trades at a trailing P/E of 333.5x and forward P/E of 68.3x. Analysts expect EPS to grow -99.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $2190.56, with bear and bull scenarios of $1380.05 and $2886.28 respectively. Model confidence stands at 37/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+29.1%
Industry Consensus
Avg Forward P/E
39.8x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LGNDLigand Pharmaceuticals Incorporated | $6.1B | $303.59 | $265.33 | -12.6% | Buy | 33.5x | 17 |
 RAREUltragenyx Pharmaceutical Inc. | $3.0B | $30.77 | $48.36 | +57.2% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $11.0B | $372.25 | $336.40 | -9.6% | Buy | 48.5x | 17 |
 PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
 ALNYAlnylam Pharmaceuticals, Inc. | $38.9B | $291.37 | $454.27 | +55.9% | Buy | 38.9x | 52 |
 BMRNBioMarin Pharmaceutical Inc. | $11.3B | $59.00 | $89.21 | +51.2% | Buy | 11.9x | 41 |
 IONSIonis Pharmaceuticals, Inc. | $13.4B | $81.18 | $106.50 | +31.2% | Buy | — | 32 |
 KALVKalVista Pharmaceuticals, Inc. | $1.4B | $27.00 | $28.67 | +6.2% | Buy | — | 13 |
PHAR — Frequently Asked Questions
Quick answers to the most common questions about buying PHAR stock.
What is the PHAR stock price target for 2026?
The consensus Wall Street price target for PHAR is $38, representing 184.9% upside from the current price of $13.34. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is PHAR a buy, sell, or hold?
PHAR has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $38 implies 184.9% upside from current levels.
Is PHAR stock overvalued or undervalued?
At a forward P/E of 68.3052x, PHAR trades at a premium valuation. The consensus price target of $38 (184.9% upside) suggests analysts still see growth justifying the multiple.
How high can PHAR stock go?
The most bullish Wall Street analyst has a price target of $40 for PHAR, while the most conservative target is $37. The consensus of $38 represents the median expectation. Our quantitative valuation model projects a bull case target of $2886 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover PHAR stock?
PHAR is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PHAR stock forecast?
The 12-month PHAR stock forecast based on 2 Wall Street analysts shows a consensus price target of $38, with estimates ranging from $37 (bear case) to $40 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $2191, with bear/bull scenarios of $1380/$2886.
What is PHAR's fair value based on fundamentals?
Our quantitative valuation model calculates PHAR's fair value at $2191 (base case), with a bear case of $1380 and bull case of $2886. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 37/100.
What is PHAR's forward P/E ratio?
PHAR trades at a forward P/E ratio of 68.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 333.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PHAR stock?
Wall Street analysts are very optimistic on PHAR, with a "Buy" consensus rating and $38 price target (184.9% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PHAR price targets vary so much?
PHAR analyst price targets range from $37 to $40, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38 consensus represents the middle ground. Our model's $1380-$2886 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare